{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:04Z","timestamp":1789560124906,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Astra Zeneca","award":["This investigator-initiated trial was funded by AstraZeneca as an externally funded research (funding provided to the participating center)."],"award-info":[{"award-number":["This investigator-initiated trial was funded by AstraZeneca as an externally funded research (funding provided to the participating center)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04464-2","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:25:46Z","timestamp":1782192346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of 1st-line durvalumab and platinum\u2013etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC)"],"prefix":"10.1007","volume":"75","author":[{"given":"Elizabeth","family":"Dudnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hovav","family":"Nechushtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Hanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Wollner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Boikaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niel","family":"Fridman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav A.","family":"Ben-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Reinhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"2","key":"4464_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1183\/13993003.00618-2015","volume":"47","author":"JL Derks","year":"2016","unstructured":"Derks JL, Hendriks LE, Buikhuisen WA, Groen HJM, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel EJM, Dingemans AMC (2016) Clinical features of pulmonary large-cell neuroendocrine carcinoma: a population-based overview. Eur Respir J 47(2):615\u2013624. https:\/\/doi.org\/10.1183\/13993003.00618-2015","journal-title":"Eur Respir J"},{"issue":"6","key":"4464_CR2","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1007\/s13277-016-5003-4","volume":"37","author":"G Lo Russo","year":"2016","unstructured":"Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC (2016) Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol 37(6):7047\u20137057. https:\/\/doi.org\/10.1007\/s13277-016-5003-4","journal-title":"Tumour Biol"},{"issue":"34","key":"4464_CR3","doi-asserted-by":"publisher","first-page":"8774","DOI":"10.1200\/JCO.2005.02.8233","volume":"23","author":"G Rossi","year":"2005","unstructured":"Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U, Facciolongo N, Maiorana A, Bavieri M, Fabbri LM, Brambilla E (2005) Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFR\u03b1, PDGFR\u03b2, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 23(34):8774\u20138785. https:\/\/doi.org\/10.1200\/JCO.2005.02.8233","journal-title":"J Clin Oncol"},{"issue":"9","key":"4464_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization classification of lung tumors. J Thorac Oncol 10(9):1243\u20131260. https:\/\/doi.org\/10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"issue":"2","key":"4464_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.lungcan.2012.04.009","volume":"77","author":"JM Sun","year":"2012","unstructured":"Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K (2012) Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer 77(2):365\u2013370. https:\/\/doi.org\/10.1016\/j.lungcan.2012.04.009","journal-title":"Lung Cancer"},{"issue":"5","key":"4464_CR6","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.cllc.2016.01.003","volume":"17","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, Kris MG, Riely GJ, Lito P, Iqbal A, Veach S, Smith-Marrone S, Sarkaria IS, Krug LM, Rudin CM, Travis WD, Rekhtman N, Pietanza MC (2016) Large cell neuroendocrine carcinoma of the lung: clinico-pathologic features, treatment, and outcomes. Clin Lung Cancer 17(5):e121\u2013e129. https:\/\/doi.org\/10.1016\/j.cllc.2016.01.003","journal-title":"Clin Lung Cancer"},{"issue":"3","key":"4464_CR7","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.cllc.2016.11.014","volume":"18","author":"G Lou","year":"2017","unstructured":"Lou G, Yu X, Song Z (2017) Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma. Clin Lung Cancer 18(3):e197\u2013e201. https:\/\/doi.org\/10.1016\/j.cllc.2016.11.014","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"4464_CR8","doi-asserted-by":"publisher","first-page":"1601838","DOI":"10.1183\/13993003.01838-2016","volume":"49","author":"JL Derks","year":"2017","unstructured":"Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC (2017) Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J 49(6):1601838. https:\/\/doi.org\/10.1183\/13993003.01838-2016","journal-title":"Eur Respir J"},{"issue":"1 Suppl","key":"4464_CR9","doi-asserted-by":"publisher","first-page":"S702","DOI":"10.1016\/j.jtho.2016.11.923","volume":"12","author":"MG Levra","year":"2017","unstructured":"Levra MG, Mazieres J, Valette CA, Molinier O, Planchard D, Frappat V, Ferrer L, Toffart AC, Sibilot DM (2017) Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: results from a French retrospective cohort. J Thorac Oncol 12(1 Suppl):S702\u2013S703. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.923","journal-title":"J Thorac Oncol"},{"key":"4464_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.lungcan.2020.03.008","volume":"143","author":"S Sherman","year":"2020","unstructured":"Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E (2020) Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer 143:40\u201346. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.008","journal-title":"Lung Cancer"},{"issue":"Suppl 16","key":"4464_CR11","doi-asserted-by":"publisher","first-page":"8576","DOI":"10.1200\/JCO.2025.43.16_suppl.8576","volume":"43","author":"P Sharma","year":"2025","unstructured":"Sharma P, Kritya M, Bansal V, Sharma P, Mahadevia H, Shrestha A (2025) Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: a systematic review and meta-analysis. J Clin Oncol 43(Suppl 16):8576. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8576","journal-title":"J Clin Oncol"},{"issue":"8","key":"4464_CR12","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.21037\/jtd-23-348","volume":"15","author":"Z Shi","year":"2023","unstructured":"Shi Z, Wei J, Xu M, Song Z (2023) Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma. J Thorac Dis 15(8):4172\u20134181. https:\/\/doi.org\/10.21037\/jtd-23-348","journal-title":"J Thorac Dis"},{"key":"4464_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108698","volume":"208","author":"R Li","year":"2025","unstructured":"Li R, Xie W, Chen R, Wu J, Wang L, Sun Y, Lin X, Xie X, Xie Z, Liu L, Liu M, Zhou C (2025) The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification. Lung Cancer 208:108698. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108698","journal-title":"Lung Cancer"},{"issue":"3","key":"4464_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14268","volume":"27","author":"N Yan","year":"2024","unstructured":"Yan N, Guo S, Zhang Z, Shen S, Li X (2024) Efficacy of immune checkpoint inhibitors in advanced large cell neuroendocrine carcinoma of the lung: a single-institution experience. Oncol Lett 27(3):135. https:\/\/doi.org\/10.3892\/ol.2024.14268","journal-title":"Oncol Lett"},{"issue":"2","key":"4464_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001999","volume":"9","author":"E Dudnik","year":"2021","unstructured":"Dudnik E, Kareff S, Moskovitz M, Kim C, Liu SV, Lobachov A, Gottfried T, Urban D, Zer A, Rotem O, Onn A, Wollner M, Bar J (2021) Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer 9(2):e001999. https:\/\/doi.org\/10.1136\/jitc-2020-001999","journal-title":"J Immunother Cancer"},{"issue":"2","key":"4464_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.31557\/APJCP.2021.22.2.365","volume":"22","author":"T Komiya","year":"2021","unstructured":"Komiya T, Ravindra N, Powell E (2021) Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pac J Cancer Prev 22(2):365\u2013370. https:\/\/doi.org\/10.31557\/APJCP.2021.22.2.365","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"4464_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12672-025-02071-8","volume":"16","author":"R Li","year":"2025","unstructured":"Li R, Zhang H, Li Y, Yao X, Dong X, Xu Y, Li Y (2025) Efficacy and safety of immunotherapy plus chemotherapy in advanced or metastatic pulmonary large-cell neuroendocrine carcinoma. Discov Oncol 16(1):316. https:\/\/doi.org\/10.1007\/s12672-025-02071-8","journal-title":"Discov Oncol"},{"issue":"17","key":"4464_CR18","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.7150\/jca.87052","volume":"14","author":"L Meng","year":"2023","unstructured":"Meng L, Cao B, Ji R, Chen DT, Laber DA, Shafique M (2023) Enhanced efficacy of chemotherapy by addition of immune checkpoint inhibitors in stage IV large cell neuroendocrine carcinoma of the lung: a real-world analysis. J Cancer 14(17):3169\u20133175. https:\/\/doi.org\/10.7150\/jca.87052","journal-title":"J Cancer"},{"issue":"suppl 16","key":"4464_CR19","doi-asserted-by":"publisher","first-page":"8106","DOI":"10.1200\/JCO.2024.42.16_suppl.8106","volume":"42","author":"A Nassar","year":"2024","unstructured":"Nassar A, Matteson K, Ardeshir F, Gray J, Baena Espinar J, Kwiatkowski D, Aboubakar Nana F, Grohe C, Citarella F, Pancirer D, Cheung J, Watson A, Sridhar A, Crowley F, Kaldas D, Kim C, Sankar K, Awosika N, Naqash A, Chiang A (2024) Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): a multicenter retrospective analysis. J Clin Oncol 42(suppl 16):8106. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8106","journal-title":"J Clin Oncol"},{"key":"4464_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108830","volume":"210","author":"FWJ Heijboer","year":"2025","unstructured":"Heijboer FWJ, Derks JL, van Nederveen FH, Hillen LM, den Bakker MA, Radonic T, Damhuis RAM (2025) Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study. Lung Cancer 210:108830. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108830","journal-title":"Lung Cancer"},{"issue":"10","key":"4464_CR21","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","volume":"26","author":"SP Patel","year":"2020","unstructured":"Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R (2020) A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res 26(10):2290\u20132296. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3356","journal-title":"Clin Cancer Res"},{"issue":"17","key":"4464_CR22","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","volume":"26","author":"O Klein","year":"2020","unstructured":"Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J (2020) Immunotherapy of Ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers. Clin Cancer Res 26(17):4454\u20134459. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0621","journal-title":"Clin Cancer Res"},{"key":"4464_CR23","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2022.03.029","volume":"169","author":"DL Chan","year":"2022","unstructured":"Chan DL, Rodriguez-Freixinos V, Doherty M, Wasson K, Iscoe N, Raskin W, Hallet J, Myrehaug S, Law C, Thawer A, Nguyen K, Singh S (2022) Avelumab in unresectable\/metastatic, progressive, grade 2\u20133 neuroendocrine neoplasms (NENs): combined results from NET-001 and NET-002 trials. Eur J Cancer 169:74\u201381. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.029","journal-title":"Eur J Cancer"},{"issue":"6","key":"4464_CR24","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/biomedicines12061161","volume":"12","author":"G Evangelou","year":"2024","unstructured":"Evangelou G, Trontzas IP, Gkiozos I, Vamvakaris I, Paraskeva C, Grammoustianou M, Gomatou G, Tsamis I, Vathiotis I, Anagnostakis M, Koliaraki V, Syrigos K (2024) The effectiveness of atezolizumab in metastatic large cell neuroendocrine carcinoma of the lungs: insights from the LANCE pilot study. Biomedicines 12(6):1161. https:\/\/doi.org\/10.3390\/biomedicines12061161","journal-title":"Biomedicines"},{"issue":"10212","key":"4464_CR25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"issue":"2","key":"4464_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 7(2):100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408","journal-title":"ESMO Open"},{"issue":"1","key":"4464_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10585-023-10250-6","volume":"41","author":"P Popov","year":"2024","unstructured":"Popov P, Steindl A, Wolff L, Bergen ES, Eckert F, Frischer JM, Widhalm G, Fuereder T, Raderer M, Berghoff AS, Preusser M, Kiesewetter B (2024) Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center. Clin Exp Metastasis 41(1):25\u201332. https:\/\/doi.org\/10.1007\/s10585-023-10250-6","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"4464_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.currproblcancer.2018.05.006","volume":"43","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Castonguay M, Wilke D, Xu Z, Plourde M, Mulroy L, MacNeil M, Bowes D (2019) Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma. Curr Probl Cancer 43(1):54\u201365. https:\/\/doi.org\/10.1016\/j.currproblcancer.2018.05.006","journal-title":"Curr Probl Cancer"},{"issue":"6","key":"4464_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100330","volume":"3","author":"Y Chen","year":"2022","unstructured":"Chen Y, Paz-Ares L, Reinmuth N, Garassino MC, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Verderame F, Havel L, Losonczy G, Conev NV, Hotta K, Ji JH, Spencer S, Dalvi T, Jiang H, Goldman JW (2022) Impact of brain metastases on treatment patterns and outcomes with first-line durvalumab plus platinum-etoposide in extensive-stage SCLC (CASPIAN): a brief report. JTO Clin Res Rep 3(6):100330. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100330","journal-title":"JTO Clin Res Rep"},{"issue":"7","key":"4464_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105325","volume":"10","author":"Y Shiraishi","year":"2025","unstructured":"Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Mizuno K, Toi Y, Daga H, Ito K, Iyama S, Taniguchi H, Morinaga R, Harada T, Inoue H, Misumi Y, Naoki K, Tobino K, Izumi M, Omori S, Tsumura S, Yamanaka Y, Sakata Y, Miura S, Mizutani H, Oki M, Iwama E, Otsubo K, Okamoto I (2025) Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED). ESMO Open 10(7):105325. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105325","journal-title":"ESMO Open"},{"key":"4464_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00293","volume":"9","author":"FWJ Heijboer","year":"2025","unstructured":"Heijboer FWJ, Brambilla M, Occhipinti M, Lorenzini D, Buikhuisen WA, Kodach LL, Christopoulos P, Stenzinger A, Hillen LM, Garrido P, Lage Y, Benito A, Lindsay CR, Carter M, Herder J, Britstra R, van der Drift MA, de Jong WK, Schutgens FWG, Damhuis RAM, Speel EM, von der Th\u00fcsen JH, Dingemans AC, Derks JL (2025) Actionable genomic alterations in large cell neuroendocrine carcinoma: a european case series of patients treated with a small molecule inhibitor. JCO Precis Oncol 9:e2500293. https:\/\/doi.org\/10.1200\/PO-25-00293","journal-title":"JCO Precis Oncol"},{"key":"4464_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911294","volume":"12","author":"D Akhoundova","year":"2022","unstructured":"Akhoundova D, Haberecker M, Fritsch R, H\u00f6ller S, Kiessling MK, Rechsteiner M, R\u00fcschoff JH, Curioni-Fontecedro A (2022) Targeting ALK in neuroendocrine tumors of the lung. Front Oncol 12:911294. https:\/\/doi.org\/10.3389\/fonc.2022.911294","journal-title":"Front Oncol"},{"key":"4464_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1227980","volume":"13","author":"Q Chen","year":"2023","unstructured":"Chen Q, Zhang J, Wang X, Zong W, Sun L, Qin J, Yin Y (2023) Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review. Front Oncol 13:1227980. https:\/\/doi.org\/10.3389\/fonc.2023.1227980","journal-title":"Front Oncol"},{"key":"4464_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1134151","volume":"13","author":"A Arora","year":"2023","unstructured":"Arora A, Zaemes J, Ozdemirli M, Kim C (2023) Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: a case report. Front Oncol 13:1134151. https:\/\/doi.org\/10.3389\/fonc.2023.1134151","journal-title":"Front Oncol"},{"key":"4464_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.101008","volume":"45","author":"H Ishii","year":"2025","unstructured":"Ishii H, Azuma K, Kiyomi F, Yoshimine K, Uchida K, Tobino K, Yamada T, Iwasa T, Kanemura H, Sumi T, Iwama E, Mori M, Takenaka M, Takeyasu Y, Kurata T, Misono S, Tanaka K, Okamoto I (2025) Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study). Cancer Treat Res Commun 45:101008. https:\/\/doi.org\/10.1016\/j.ctarc.2025.101008","journal-title":"Cancer Treat Res Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04464-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:24Z","timestamp":1789556544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04464-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4464"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04464-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of interest statement ED reports research grants from AstraZeneca (Inst.), Boehringer Ingelheim (Inst.), and Takeda (Inst.), honoraria\/consulting\/advisory fees from Roche, Merck Sharpe & Dohme, Bristol-Myers Squibb, AstraZeneca, Takeda, Pfizer, Novartis, Janssen, Sanofi, Merck Serono, Medison, Rhenium, and Progenetics, also serves a member of the Assuta IRB Committee. HN is a co-inventor on a patent for LY6K-targeting antibodies and a member of the Hadassah IRB Committee. OR reports honoraria\/consulting\/advisory fees\/travel support from AstraZeneca, Boehringer Ingelheim, Merck Sharpe & Dohme, Bristol-Myers Squibb, Novartis, Pfizer, Roche, Takeda, Teva, Rhenium. DR reports honoraria\/consulting\/advisory fees from AstraZeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards. Approval from the Assuta Institutional Helsinki Committee was obtained prior to study initiation (protocol approval number ASMC-0072\u201321).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for trial participation was obtained from all participants; no identifiable individual-level data are reported in this manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (version 5.1; OpenAI) to provide language editing and writing assistance. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication\n                      .","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}